Literature DB >> 32434589

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.

Lori J Goldstein1, Raymond P Perez2,3, Denise Yardley4,5, Linda K Han6,7, James M Reuben8, Hui Gao8, Susan McCanna9, Beth Butler9, Pier Adelchi Ruffini9, Yi Liu10, Roberto R Rosato10, Jenny C Chang11.   

Abstract

An amendment to this paper has been published and can be accessed via the original article.

Entities:  

Year:  2020        PMID： 32434589      PMCID： PMC7238734          DOI： 10.1186/s13058-020-01294-7

Source DB:  PubMed          Journal:  Breast Cancer Res        ISSN： 1465-5411            Impact factor:   6.466


Correction to: Breast Cancer Res (2020) 22:4 https://doi.org/10.1186/s13058-019-1243-8 After publication of the original article [1], the authors identified two errors in the Author details: Sarah Cannon Research Institute, Nashville, TN, should be added to Dr. Yardley’s affiliation in addition to Tennessee Oncology. Dr. Yardley has provided services to multiple companies on behalf of Sarah Cannon Research Institute.
  1 in total

1.  A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.

Authors:  Lori J Goldstein; Raymond P Perez; Denise Yardley; Linda K Han; James M Reuben; Hui Gao; Susan McCanna; Beth Butler; Pier Adelchi Ruffini; Yi Liu; Roberto R Rosato; Jenny C Chang
Journal:  Breast Cancer Res       Date:  2020-01-10       Impact factor: 6.466
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.